Pharmaceutical Price Regulation Scheme
The Pharmaceutical Price Regulation Scheme (PPRS) is the mechanism used by the
The current PPRS scheme, using a value-based pricing mechanism, came into effect on 1 January 2014, to run for no less than five years.[1] It replaced an earlier scheme running from 2009 to 2013.[2]
In December 2014
On 23 August 2017, the UK Government launched a consultation relating to the PPRS, following legislation that was recently passed.
Purpose and objectives
As the primary buyer of medicines in the UK, the Department of Health has an interest in ensuring medicines are available at reasonable prices. However it is also important that pharmaceutical companies, represented by the ABPI, are able to maintain sufficient levels of
- Deliver value for money
- Encourage innovation
- Promote access and uptake for new medicines
- Provide stability, sustainability and predictability
Patient access schemes
The 2009 PPRS agreement allows for patient access schemes. These allow for the provision of a drug which would not otherwise be supported by
References
- ^ "Pharmaceutical price regulation scheme 2014 - GOV.UK". www.gov.uk. Retrieved 4 March 2017.
- ^ Department of Health The Pharmaceutical Price Regulation Scheme 2009
- ^ "Appeal finds NICE decision on £90k breast cancer drug 'unfair'". Health Service Journal. 16 December 2015. Retrieved 11 January 2015.